Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Total Non-current Assets
All assets not expected to be converted to cash within one year.
Annovis Bio, Inc.NYSE: ANVS
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets remains negative
Q1 FY2026 total non-current assets was $0, compared with $0 a year earlier.
Context
- Total non-current assets amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total non-current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Non-current Assets vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's Mar 2026 total non-current assets of $0 is the lowest of the 6 companies compared; the peer median is $2.42M.
- Total non-current assets amounts to 0.0% of total assets for ANVS, versus a peer median of 7.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $95.01M | -15.3% | -36.3% | 88.5% | |
| Mar 2026 | $6.6M | -18.3% | -15.6% | 34.4% | |
| Jun 2026 | $2.42M | +21.6% | -9.7% | 6.0% | |
| Mar 2026 | $1.78M | -61.0% | +61.9% | 7.2% | |
| Mar 2026 | $7.52K | +168.5% | -76.4% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ANVS) | $2.42M | -15.3% | -15.6% | 7.2% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.